Worldwide Lewy Body Dementia Treatment Industry to 2027 - Featuring Teva Pharmaceuticals, Bayer and Sanofi Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Lewy Body Dementia Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Type; By Indication; By Distribution Channel; By Regions Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global Lewy body dementia treatment market size is predicted to reach USD 5.31 billion by 2027. This report gives a detailed insight into current market dynamics and provides analysis on future market growth.

Lewy body dementia is a progressive disorder associated with dysfunction of the central nervous system and characterized by deposits of alpha-synuclein, a protein in the brain. The unusual deposits in the brain formed Lewy bodies, which can lead to several problems with body movement, thinking, mood, and behavior. Lewy body dementia is the most common disease after Alzheimer's which is rapidly growing and subsequently foster global market growth. Recent developments include the new launches and clinical studies such as LY3154207, ABBV-0805, etc. The launches of drugs are associated with the diagnosis of dementia with Lewy body, Parkinson's, and Alzheimer's diseases which further leads to drive the growth of the global market.

The prominent factors favoring the global market growth include the rising initiatives by the legal and regulatory authorities to develop an effective and safe treatment for the LBD disorder in the patients. For instance, in October 2019, an LBD Association Research Center of Excellence, Georgetown University Medical Center, has taken the initiative to offer 3 clinical trials to devise new methods and treatments for Lewy body dementia and Alzheimer's disease.

Rising incidences of getting affected by Alzheimer's disease and related disorders include vascular dementia, Lewy body dementia, frontotemporal degeneration, and Parkinson's disease has witnessed the surge in demand for the treatment of the patients. The regulatory authorities and researchers are engaged in discovering new methods and solutions to provide effective treatment of the disorder.

For instance, in June 2020, The Harry T. Mangurian, Jr. Foundation and Florida Atlantic University's Schmidt College of Medicine have amalgamated its forces to discover and research medicine to prevent dementia. The grant of USD 3 million will allow FAU's Schmidt College of Medicine to establish a new FAU Center for Brain Health. Furthermore, in July 2020, the Journal of the American Medical Association (JAMA) has published that researchers have formed a new p-tau217 blood test, which is proved to hold remarkable results in the diagnosis of Alzheimer's disease and related disorders in the patients.

Additionally, the rising prevalence of the progressive diseases of dementia has raised the need for effective treatment to treat the disease and prevent risk in the patients which further leads to drive growth. The growing awareness of the symptoms of the disease and the advancement in healthcare technology to develop new methods and drugs for the treatment of patients is likely to surge the market growth.

Companies Mentioned

• Mallinckrodt Pharmaceuticals
• BioArctic AB
• Bausch Health Companies Inc.
• Sumitomo Dainippon Pharma Co. Ltd.
• Janssen Pharmaceuticals Inc.
• Jazz Pharmaceuticals Inc.
• Allergan Plc.
• Noven Pharmaceuticals Inc.
• Takeda Pharmaceutical Company Ltd.
• Eli Lilly and Company
• Eisai Co. Ltd.
• Novartis AG
• GlaxoSmithKline
• Pfizer Inc.
• Teva Pharmaceuticals
• Bayer AG
• Sanofi AG
• Mylan NV

Key Topics Covered:

1. Introduction

1.1. Report Description

1.1.1. Objectives of the Study

1.1.2. Market Scope

1.1.3. Assumptions

1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview

3.1.1. Data Mining

3.2. Data Sources

3.2.1. Primary Sources

3.2.2. Secondary Sources

4. Lewy Body Dementia Treatment Market Insights

4.1. Lewy Body Dementia Treatment - Industry snapshot

4.2. Lewy Body Dementia Treatment Market Dynamics

4.2.1. Drivers and Opportunities

4.2.1.1. Prevalence of Lewy body dementia

4.2.1.2. Affordable Treatment Options

4.2.2. Restraints and Challenges

4.2.2.1. Drug side-effects

4.3. Porter's Five Forces Analysis

4.4. PESTLE Analysis

4.5. Lewy Body Dementia Treatment Market Industry trends

5. Lewy Body Dementia Treatment Market Assessment by Drug Type

5.1. Key Findings

5.2. Introduction

5.3. Modafinil

5.4. Cholinesterase Inhibitors

5.5. Benzodiazepine

5.6. Antipsychotic Drugs

5.7. Antidepressants

5.8. Carbidopa-Levodopa

6. Lewy Body Dementia Treatment Market Assessment by Indication

6.1. Key Findings

6.2. Introduction

6.3. Parkinson's Disease

6.4. Dementia with Lewy Bodies (DLB)

7. Lewy Body Dementia Treatment Market Assessment by Distribution Channel

7.1. Key Findings

7.2. Introduction

7.3. Drug Stores

7.4. Hospitals Pharmacies

7.5. Online Pharmacies

7.6. Retail Pharmacies

8. Lewy Body Dementia Treatment Market Assessment by Geography

8.1. Key findings

8.2. Introduction

8.3. Lewy Body Dementia Treatment Market - North America

8.4. Lewy Body Dementia Treatment Market - Europe

8.5. Lewy Body Dementia Treatment Market - Asia-Pacific

8.6. Lewy Body Dementia Treatment Market - Middle East & Africa

8.7. Lewy Body Dementia Treatment Market - Latin America

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis

9.1.1. Expansion

9.1.2. Acquisitions

9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/l0uuxk